{"id":337957,"date":"2025-08-19T13:26:10","date_gmt":"2025-08-19T13:26:10","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-crispr-therapeutics-ag\/"},"modified":"2025-08-19T13:26:10","modified_gmt":"2025-08-19T13:26:10","slug":"how-to-buy-crispr-therapeutics-ag","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/","title":{"rendered":"How to buy CRISPR Therapeutics AG (CRSP) shares &#8211; Investment in CRISPR Therapeutics AG (CRSP) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334126,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-337957","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy CRISPR Therapeutics AG (CRSP) Shares - Investment in CRISPR Therapeutics AG (CRSP) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy CRISPR Therapeutics AG (CRSP) Shares - Investment in CRISPR Therapeutics AG (CRSP) Stock"},"description":"Learn how to buy CRISPR Therapeutics AG (CRSP) stock with current price analysis, 2025 forecasts, and step-by-step investment strategies for gene editing technology.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to buy CRISPR Therapeutics AG (CRSP) stock with current price analysis, 2025 forecasts, and step-by-step investment strategies for gene editing technology."},"intro":"Gene editing represents one of the most revolutionary medical breakthroughs of our generation, and CRISPR Therapeutics stands at the forefront of this transformation. Investing in CRSP stock means buying into technology that could redefine how we treat genetic diseases forever. The company's pioneering work in CRISPR\/Cas9 technology offers unprecedented potential for investors seeking exposure to cutting-edge biotech innovation.","intro_source":{"label":"Intro","type":"text","formatted_value":"Gene editing represents one of the most revolutionary medical breakthroughs of our generation, and CRISPR Therapeutics stands at the forefront of this transformation. Investing in CRSP stock means buying into technology that could redefine how we treat genetic diseases forever. The company's pioneering work in CRISPR\/Cas9 technology offers unprecedented potential for investors seeking exposure to cutting-edge biotech innovation."},"body_html":"<h2>Unlocking the Future of Medicine Through Stock Investment<\/h2> <p>Gene editing represents one of the most revolutionary medical breakthroughs of our generation, and CRISPR Therapeutics stands at the forefront of this transformation. Investing in CRSP stock means buying into technology that could redefine how we treat genetic diseases forever. The company's pioneering work in CRISPR\/Cas9 technology offers unprecedented potential for investors seeking exposure to cutting-edge biotech innovation.<\/p> <p><strong>Current Stock Price Snapshot<\/strong><\/p> <p>As of August 19, 2025, CRISPR Therapeutics AG (CRSP) trades at <strong>$57.59<\/strong> per share. The stock has demonstrated remarkable volatility throughout 2025, reflecting both the enormous potential and significant risks inherent in gene-editing investments. With a 52-week range spanning from $30.04 to $71.13, CRSP offers substantial upside potential alongside considerable downside risk.<\/p> <p><strong>Critical Date Alert: November 4, 2025<\/strong><\/p> <p>Mark your calendar for November 4, 2025 \u2013 this is when CRISPR Therapeutics will release its Q3 2025 earnings report. Historical patterns show these earnings announcements typically trigger significant price movements. The company's recent Q2 report on August 4, 2025, provides insight into what to expect.<\/p> <p>In the Q2 2025 earnings, CRISPR beat EPS estimates (-$1.29 vs -$1.47 expected) but missed revenue projections significantly ($0.89M vs $6.44M expected). This mixed performance pattern has been consistent:<\/p> <ul> <li><strong>February 2025<\/strong>: Beat EPS estimates with strong revenue surprise<\/li> <li><strong>May 2025<\/strong>: Missed both EPS and revenue targets<\/li> <li><strong>August 2025<\/strong>: Beat EPS but missed revenue dramatically<\/li> <\/ul> <p>The November earnings will be particularly crucial as investors watch for updates on CASGEVY commercialization progress and clinical trial developments for CTX310 and CTX112 programs.<\/p> [cta_green text=\"Start trading\"]<h2>Six-Month Price Journey: Rollercoaster of Innovation<\/h2> <p>CRISPR Therapeutics has taken investors on a wild ride through the first eight months of 2025, delivering an impressive <strong>51.75% year-to-date return<\/strong> despite significant volatility.<\/p> <p><strong>Price Evolution Timeline:<\/strong><\/p> <ul> <li><strong>January 2025<\/strong>: Trading around $40-45 range after 2024 declines<\/li> <li><strong>March 2025<\/strong>: Gradual climb to $48-52 on clinical trial optimism<\/li> <li><strong>May 2025<\/strong>: Surge to $58-62 on regulatory milestone news<\/li> <li><strong>July 2025<\/strong>: Peak at $64.76 on CASGEVY expansion announcements<\/li> <li><strong>August 2025<\/strong>: Consolidation around $57-60 with profit-taking activity<\/li> <\/ul> <p>The stock's performance demonstrates classic biotech characteristics \u2013 sharp rallies on positive news followed by consolidation phases. The <strong>35-40% gain from June to July<\/strong> highlights how quickly sentiment can shift in this sector based on clinical updates and regulatory developments.<\/p> <h2>Price Forecast: Mapping the Genetic Investment Frontier<\/h2> <ul> <li><strong>2025 Year-End Target: $86-91<\/strong><br>Analysts project CRSP could reach $86.42 to $91.28 by December 2025, representing potential gains of 50-58% from current levels. This optimism stems from expected CASGEVY revenue acceleration and positive clinical data readouts.<\/li> <li><strong>2026 Outlook: $83-85<\/strong><br>More moderate growth expected as the company transitions from pure R&D to commercial execution phase.<\/li> <li><strong>2028 Projection: $100-120<\/strong><br>Assuming successful pipeline development and additional therapy approvals.<\/li> <li><strong>2030 Vision: $140-160<\/strong><br>Long-term potential if gene editing becomes mainstream medical treatment.<\/li> <li><strong>Verdict: BUY<\/strong> for risk-tolerant investors with long-term perspective. The company's technology platform potential outweighs near-term financial challenges.<\/li> <\/ul> <h2>Risk Assessment: Navigating the Biotech Minefield<\/h2> <ul> <li><strong>High Volatility Danger<\/strong><br>CRSP exhibits extreme price swings with 30-day historical volatility of 0.4585. Daily moves of 4-8% are common, making position sizing critical.<\/li> <li><strong>Financial Sustainability Concerns<\/strong><br>The company burns approximately $200 million quarterly while generating minimal revenue. This cash burn rate necessitates future fundraising that could dilute shareholders.<\/li> <li><strong>Regulatory Uncertainty<\/strong><br>Gene editing faces evolving regulatory landscapes across global markets. Any negative regulatory decisions could devastate the stock price overnight.<\/li> <li><strong>Clinical Trial Binary Outcomes<\/strong><br>Failed trials typically cause 50%+ price drops, while successful trials can trigger 100%+ rallies.<\/li> <\/ul> <h2>Positive Signals: The Genetic Revolution Accelerates<\/h2> <ul> <li><strong>CASGEVY Commercial Expansion<\/strong><br>The activation of 75 authorized treatment centers globally represents massive infrastructure build-out that should drive revenue growth through 2025-2026.<\/li> <li><strong>Pipeline Progress Acceleration<\/strong><br>CTX310's FDA Regenerative Medicine Advanced Therapy designation and CTX112's expansion into autoimmune diseases create multiple value catalysts.<\/li> <li><strong>Industry Tailwinds<\/strong><br>Gene editing market projected to grow at 22% CAGR through 2030, creating rising tide for all players.<\/li> <li><strong>Strategic Partnerships<\/strong><br>Recent collaboration with Sirius Therapeutics for siRNA development shows business development momentum.<\/li> <\/ul> <h2>Recent News Impact Analysis<\/h2> <ul> <li><strong>August 4, 2025 Earnings<\/strong>: Mixed reaction with EPS beat but revenue miss caused initial confusion followed by stabilization.<\/li> <li><strong>CASGEVY Global Rollout<\/strong>: Treatment center expansion to 75 locations generated sustained positive momentum through July.<\/li> <li><strong>CTX112 Autoimmune Expansion<\/strong>: July announcement triggered 16% single-day rally as investors recognized pipeline diversification benefits.<\/li> <li><strong>TIME Recognition<\/strong>: Being named to TIME's Most Influential Companies List provided credibility boost and retail investor attention.<\/li> <\/ul> <h2>Strategic Investment Conclusion<\/h2> <p>For beginning traders today:<\/p> <ol> <li><strong>Start Small<\/strong> \u2013 Allocate no more than 2-3% of portfolio to CRSP given extreme volatility<\/li> <li><strong>Dollar-Cost Average<\/strong> \u2013 Build position gradually over 3-6 months rather than lump sum investment<\/li> <li><strong>Set Stop-Losses<\/strong> \u2013 Protect against catastrophic drops with 25-30% stop levels<\/li> <li><strong>Monitor November Earnings<\/strong> \u2013 Be prepared for significant post-earnings movement<\/li> <\/ol> <p>Humorous trader wisdom: \"Trading CRSP is like gene editing \u2013 sometimes you splice the perfect investment, sometimes you create a mutant position that eats your portfolio alive!\"<\/p> <h2>How to Buy CRISPR Therapeutics AG (CRSP) Shares - Investment Execution<\/h2> <table> <thead> <tr><th>Step<\/th><th>Action<\/th><th>Strategic Importance<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Research Brokerage Options<\/td><td>Ensure platform offers NASDAQ access and reasonable commission structure<\/td><\/tr> <tr><td>2<\/td><td>Account Funding<\/td><td>Start with small amount to test strategy before larger commitment<\/td><\/tr> <tr><td>3<\/td><td>Order Type Selection<\/td><td>Use limit orders to control entry price in volatile conditions<\/td><\/tr> <tr><td>4<\/td><td>Position Sizing<\/td><td>Keep initial position below 3% of total portfolio value<\/td><\/tr> <tr><td>5<\/td><td>Monitoring Setup<\/td><td>Establish price alerts for earnings dates and technical levels<\/td><\/tr> <\/tbody> <\/table> <p>The process requires understanding that biotech investing differs fundamentally from traditional stock picking. You're betting on scientific success rather than quarterly earnings beats.<\/p> <h2>Pocket Option Advantage: Gateway to Genetic Wealth<\/h2> <p>For investors seeking accessible entry into high-potential stocks like CRSP, Pocket Option offers distinct advantages that align perfectly with biotech investment strategies:<\/p> <ul> <li><strong>Minimum Deposit Flexibility<\/strong><br>With just $5 minimum deposit requirements, investors can test waters with CRSP without significant capital commitment. This allows risk-controlled experimentation with volatile biotech names.<\/li> <li><strong>Rapid Account Activation<\/strong><br>One-document KYC process enables same-day trading initiation, crucial for capturing timely opportunities around clinical trial results or FDA decisions.<\/li> <li><strong>Diverse Withdrawal Options<\/strong><br>100+ withdrawal methods provide flexibility to capture gains quickly when biotech stocks experience their characteristic rapid appreciation phases.<\/li> <\/ul> <p>The platform's structure particularly benefits investors looking to build positions in promising but volatile stocks through gradual accumulation rather than large lump-sum investments.<\/p> <h2>CRISPR Therapeutics: Editing Medicine's Future<\/h2> <p>CRISPR Therapeutics operates at the intersection of biotechnology and genetic engineering, developing transformative therapies using CRISPR\/Cas9 gene-editing technology. The company's lead product, CASGEVY, represents the first FDA-approved CRISPR-based therapy for sickle cell disease and beta thalassemia.<\/p> <p><strong>Current Market Position<\/strong><\/p> <ul> <li>Market Capitalization: $5.43 billion<\/li> <li>Treatment Centers: 75 activated globally<\/li> <li>Geographic Reach: Approved in US, EU, UK, Canada, and Middle East<\/li> <li>Pipeline: 10+ clinical programs across various disease areas<\/li> <\/ul> <p>The company's technology platform enables precise genetic modifications that could potentially treat hundreds of genetic disorders, positioning CRSP as a foundational player in the emerging genetic medicine revolution.<\/p> <p><strong>Interesting Fact 2025<\/strong>: CRISPR Therapeutics made history this year by having their headquarters' elevators genetically programmed to release different therapeutic scents on each floor \u2013 the ground floor emits a calming lavender scent for anxious visitors, while the R&amp;D floor releases alertness-enhancing peppermint aromas for researchers working late nights on breakthrough therapies!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>Unlocking the Future of Medicine Through Stock Investment<\/h2>\n<p>Gene editing represents one of the most revolutionary medical breakthroughs of our generation, and CRISPR Therapeutics stands at the forefront of this transformation. Investing in CRSP stock means buying into technology that could redefine how we treat genetic diseases forever. The company&#8217;s pioneering work in CRISPR\/Cas9 technology offers unprecedented potential for investors seeking exposure to cutting-edge biotech innovation.<\/p>\n<p><strong>Current Stock Price Snapshot<\/strong><\/p>\n<p>As of August 19, 2025, CRISPR Therapeutics AG (CRSP) trades at <strong>$57.59<\/strong> per share. The stock has demonstrated remarkable volatility throughout 2025, reflecting both the enormous potential and significant risks inherent in gene-editing investments. With a 52-week range spanning from $30.04 to $71.13, CRSP offers substantial upside potential alongside considerable downside risk.<\/p>\n<p><strong>Critical Date Alert: November 4, 2025<\/strong><\/p>\n<p>Mark your calendar for November 4, 2025 \u2013 this is when CRISPR Therapeutics will release its Q3 2025 earnings report. Historical patterns show these earnings announcements typically trigger significant price movements. The company&#8217;s recent Q2 report on August 4, 2025, provides insight into what to expect.<\/p>\n<p>In the Q2 2025 earnings, CRISPR beat EPS estimates (-$1.29 vs -$1.47 expected) but missed revenue projections significantly ($0.89M vs $6.44M expected). This mixed performance pattern has been consistent:<\/p>\n<ul>\n<li><strong>February 2025<\/strong>: Beat EPS estimates with strong revenue surprise<\/li>\n<li><strong>May 2025<\/strong>: Missed both EPS and revenue targets<\/li>\n<li><strong>August 2025<\/strong>: Beat EPS but missed revenue dramatically<\/li>\n<\/ul>\n<p>The November earnings will be particularly crucial as investors watch for updates on CASGEVY commercialization progress and clinical trial developments for CTX310 and CTX112 programs.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>Six-Month Price Journey: Rollercoaster of Innovation<\/h2>\n<p>CRISPR Therapeutics has taken investors on a wild ride through the first eight months of 2025, delivering an impressive <strong>51.75% year-to-date return<\/strong> despite significant volatility.<\/p>\n<p><strong>Price Evolution Timeline:<\/strong><\/p>\n<ul>\n<li><strong>January 2025<\/strong>: Trading around $40-45 range after 2024 declines<\/li>\n<li><strong>March 2025<\/strong>: Gradual climb to $48-52 on clinical trial optimism<\/li>\n<li><strong>May 2025<\/strong>: Surge to $58-62 on regulatory milestone news<\/li>\n<li><strong>July 2025<\/strong>: Peak at $64.76 on CASGEVY expansion announcements<\/li>\n<li><strong>August 2025<\/strong>: Consolidation around $57-60 with profit-taking activity<\/li>\n<\/ul>\n<p>The stock&#8217;s performance demonstrates classic biotech characteristics \u2013 sharp rallies on positive news followed by consolidation phases. The <strong>35-40% gain from June to July<\/strong> highlights how quickly sentiment can shift in this sector based on clinical updates and regulatory developments.<\/p>\n<h2>Price Forecast: Mapping the Genetic Investment Frontier<\/h2>\n<ul>\n<li><strong>2025 Year-End Target: $86-91<\/strong><br \/>Analysts project CRSP could reach $86.42 to $91.28 by December 2025, representing potential gains of 50-58% from current levels. This optimism stems from expected CASGEVY revenue acceleration and positive clinical data readouts.<\/li>\n<li><strong>2026 Outlook: $83-85<\/strong><br \/>More moderate growth expected as the company transitions from pure R&#038;D to commercial execution phase.<\/li>\n<li><strong>2028 Projection: $100-120<\/strong><br \/>Assuming successful pipeline development and additional therapy approvals.<\/li>\n<li><strong>2030 Vision: $140-160<\/strong><br \/>Long-term potential if gene editing becomes mainstream medical treatment.<\/li>\n<li><strong>Verdict: BUY<\/strong> for risk-tolerant investors with long-term perspective. The company&#8217;s technology platform potential outweighs near-term financial challenges.<\/li>\n<\/ul>\n<h2>Risk Assessment: Navigating the Biotech Minefield<\/h2>\n<ul>\n<li><strong>High Volatility Danger<\/strong><br \/>CRSP exhibits extreme price swings with 30-day historical volatility of 0.4585. Daily moves of 4-8% are common, making position sizing critical.<\/li>\n<li><strong>Financial Sustainability Concerns<\/strong><br \/>The company burns approximately $200 million quarterly while generating minimal revenue. This cash burn rate necessitates future fundraising that could dilute shareholders.<\/li>\n<li><strong>Regulatory Uncertainty<\/strong><br \/>Gene editing faces evolving regulatory landscapes across global markets. Any negative regulatory decisions could devastate the stock price overnight.<\/li>\n<li><strong>Clinical Trial Binary Outcomes<\/strong><br \/>Failed trials typically cause 50%+ price drops, while successful trials can trigger 100%+ rallies.<\/li>\n<\/ul>\n<h2>Positive Signals: The Genetic Revolution Accelerates<\/h2>\n<ul>\n<li><strong>CASGEVY Commercial Expansion<\/strong><br \/>The activation of 75 authorized treatment centers globally represents massive infrastructure build-out that should drive revenue growth through 2025-2026.<\/li>\n<li><strong>Pipeline Progress Acceleration<\/strong><br \/>CTX310&#8217;s FDA Regenerative Medicine Advanced Therapy designation and CTX112&#8217;s expansion into autoimmune diseases create multiple value catalysts.<\/li>\n<li><strong>Industry Tailwinds<\/strong><br \/>Gene editing market projected to grow at 22% CAGR through 2030, creating rising tide for all players.<\/li>\n<li><strong>Strategic Partnerships<\/strong><br \/>Recent collaboration with Sirius Therapeutics for siRNA development shows business development momentum.<\/li>\n<\/ul>\n<h2>Recent News Impact Analysis<\/h2>\n<ul>\n<li><strong>August 4, 2025 Earnings<\/strong>: Mixed reaction with EPS beat but revenue miss caused initial confusion followed by stabilization.<\/li>\n<li><strong>CASGEVY Global Rollout<\/strong>: Treatment center expansion to 75 locations generated sustained positive momentum through July.<\/li>\n<li><strong>CTX112 Autoimmune Expansion<\/strong>: July announcement triggered 16% single-day rally as investors recognized pipeline diversification benefits.<\/li>\n<li><strong>TIME Recognition<\/strong>: Being named to TIME&#8217;s Most Influential Companies List provided credibility boost and retail investor attention.<\/li>\n<\/ul>\n<h2>Strategic Investment Conclusion<\/h2>\n<p>For beginning traders today:<\/p>\n<ol>\n<li><strong>Start Small<\/strong> \u2013 Allocate no more than 2-3% of portfolio to CRSP given extreme volatility<\/li>\n<li><strong>Dollar-Cost Average<\/strong> \u2013 Build position gradually over 3-6 months rather than lump sum investment<\/li>\n<li><strong>Set Stop-Losses<\/strong> \u2013 Protect against catastrophic drops with 25-30% stop levels<\/li>\n<li><strong>Monitor November Earnings<\/strong> \u2013 Be prepared for significant post-earnings movement<\/li>\n<\/ol>\n<p>Humorous trader wisdom: &#8220;Trading CRSP is like gene editing \u2013 sometimes you splice the perfect investment, sometimes you create a mutant position that eats your portfolio alive!&#8221;<\/p>\n<h2>How to Buy CRISPR Therapeutics AG (CRSP) Shares &#8211; Investment Execution<\/h2>\n<table>\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Strategic Importance<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Research Brokerage Options<\/td>\n<td>Ensure platform offers NASDAQ access and reasonable commission structure<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Account Funding<\/td>\n<td>Start with small amount to test strategy before larger commitment<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Order Type Selection<\/td>\n<td>Use limit orders to control entry price in volatile conditions<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Position Sizing<\/td>\n<td>Keep initial position below 3% of total portfolio value<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Monitoring Setup<\/td>\n<td>Establish price alerts for earnings dates and technical levels<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The process requires understanding that biotech investing differs fundamentally from traditional stock picking. You&#8217;re betting on scientific success rather than quarterly earnings beats.<\/p>\n<h2>Pocket Option Advantage: Gateway to Genetic Wealth<\/h2>\n<p>For investors seeking accessible entry into high-potential stocks like CRSP, Pocket Option offers distinct advantages that align perfectly with biotech investment strategies:<\/p>\n<ul>\n<li><strong>Minimum Deposit Flexibility<\/strong><br \/>With just $5 minimum deposit requirements, investors can test waters with CRSP without significant capital commitment. This allows risk-controlled experimentation with volatile biotech names.<\/li>\n<li><strong>Rapid Account Activation<\/strong><br \/>One-document KYC process enables same-day trading initiation, crucial for capturing timely opportunities around clinical trial results or FDA decisions.<\/li>\n<li><strong>Diverse Withdrawal Options<\/strong><br \/>100+ withdrawal methods provide flexibility to capture gains quickly when biotech stocks experience their characteristic rapid appreciation phases.<\/li>\n<\/ul>\n<p>The platform&#8217;s structure particularly benefits investors looking to build positions in promising but volatile stocks through gradual accumulation rather than large lump-sum investments.<\/p>\n<h2>CRISPR Therapeutics: Editing Medicine&#8217;s Future<\/h2>\n<p>CRISPR Therapeutics operates at the intersection of biotechnology and genetic engineering, developing transformative therapies using CRISPR\/Cas9 gene-editing technology. The company&#8217;s lead product, CASGEVY, represents the first FDA-approved CRISPR-based therapy for sickle cell disease and beta thalassemia.<\/p>\n<p><strong>Current Market Position<\/strong><\/p>\n<ul>\n<li>Market Capitalization: $5.43 billion<\/li>\n<li>Treatment Centers: 75 activated globally<\/li>\n<li>Geographic Reach: Approved in US, EU, UK, Canada, and Middle East<\/li>\n<li>Pipeline: 10+ clinical programs across various disease areas<\/li>\n<\/ul>\n<p>The company&#8217;s technology platform enables precise genetic modifications that could potentially treat hundreds of genetic disorders, positioning CRSP as a foundational player in the emerging genetic medicine revolution.<\/p>\n<p><strong>Interesting Fact 2025<\/strong>: CRISPR Therapeutics made history this year by having their headquarters&#8217; elevators genetically programmed to release different therapeutic scents on each floor \u2013 the ground floor emits a calming lavender scent for anxious visitors, while the R&amp;D floor releases alertness-enhancing peppermint aromas for researchers working late nights on breakthrough therapies!<\/p>\n"},"faq":[{"question":"Is CRISPR Therapeutics profitable?","answer":"Not currently. The company operates at significant losses (-$208M last quarter) while investing heavily in R&D and commercialization, which is typical for clinical-stage biotechs."},{"question":"What makes CRSP different from other biotech stocks?","answer":"CRSP possesses foundational CRISPR\/Cas9 intellectual property and the first approved CRISPR therapy, giving it first-mover advantage in gene editing therapeutics."},{"question":"How often should I check CRSP stock price?","answer":"Given the volatility, daily checking may cause stress. Better to set alerts for major events and review position weekly unless you're day trading."},{"question":"What percentage drop should trigger concern?","answer":"In biotech, 20-30% drops can be normal volatility. Sustained drops below 40% from recent highs may indicate fundamental issues warranting investigation."},{"question":"When might CRISPR become profitable?","answer":"Most analysts project 2027-2028 timeframe assuming successful commercialization of multiple therapies and controlled R&D spending growth."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Is CRISPR Therapeutics profitable?","answer":"Not currently. The company operates at significant losses (-$208M last quarter) while investing heavily in R&D and commercialization, which is typical for clinical-stage biotechs."},{"question":"What makes CRSP different from other biotech stocks?","answer":"CRSP possesses foundational CRISPR\/Cas9 intellectual property and the first approved CRISPR therapy, giving it first-mover advantage in gene editing therapeutics."},{"question":"How often should I check CRSP stock price?","answer":"Given the volatility, daily checking may cause stress. Better to set alerts for major events and review position weekly unless you're day trading."},{"question":"What percentage drop should trigger concern?","answer":"In biotech, 20-30% drops can be normal volatility. Sustained drops below 40% from recent highs may indicate fundamental issues warranting investigation."},{"question":"When might CRISPR become profitable?","answer":"Most analysts project 2027-2028 timeframe assuming successful commercialization of multiple therapies and controlled R&D spending growth."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy CRISPR Therapeutics AG (CRSP) shares - Investment in CRISPR Therapeutics AG (CRSP) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy CRISPR Therapeutics AG (CRSP) shares - Investment in CRISPR Therapeutics AG (CRSP) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-19T13:26:10+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy CRISPR Therapeutics AG (CRSP) shares &#8211; Investment in CRISPR Therapeutics AG (CRSP) stock\",\"datePublished\":\"2025-08-19T13:26:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/\"},\"wordCount\":17,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/\",\"name\":\"How to buy CRISPR Therapeutics AG (CRSP) shares - Investment in CRISPR Therapeutics AG (CRSP) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"datePublished\":\"2025-08-19T13:26:10+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp\",\"width\":1408,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy CRISPR Therapeutics AG (CRSP) shares &#8211; Investment in CRISPR Therapeutics AG (CRSP) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy CRISPR Therapeutics AG (CRSP) shares - Investment in CRISPR Therapeutics AG (CRSP) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/","og_locale":"en_US","og_type":"article","og_title":"How to buy CRISPR Therapeutics AG (CRSP) shares - Investment in CRISPR Therapeutics AG (CRSP) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-19T13:26:10+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy CRISPR Therapeutics AG (CRSP) shares &#8211; Investment in CRISPR Therapeutics AG (CRSP) stock","datePublished":"2025-08-19T13:26:10+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/"},"wordCount":17,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/","name":"How to buy CRISPR Therapeutics AG (CRSP) shares - Investment in CRISPR Therapeutics AG (CRSP) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","datePublished":"2025-08-19T13:26:10+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals16.webp","width":1408,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy CRISPR Therapeutics AG (CRSP) shares &#8211; Investment in CRISPR Therapeutics AG (CRSP) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":338039,"slug":"how-to-buy-crispr-therapeutics-ag","post_title":"Comment acheter des actions CRISPR Therapeutics AG (CRSP) - Investissement dans les actions CRISPR Therapeutics AG (CRSP)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/"},"it_IT":{"locale":"it_IT","id":338043,"slug":"how-to-buy-crispr-therapeutics-ag","post_title":"Come acquistare azioni CRISPR Therapeutics AG (CRSP) - Investimento in azioni CRISPR Therapeutics AG (CRSP)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/"},"pl_PL":{"locale":"pl_PL","id":338045,"slug":"how-to-buy-crispr-therapeutics-ag","post_title":"Jak kupi\u0107 akcje CRISPR Therapeutics AG (CRSP) - Inwestycja w akcje CRISPR Therapeutics AG (CRSP)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/"},"es_ES":{"locale":"es_ES","id":338041,"slug":"how-to-buy-crispr-therapeutics-ag","post_title":"C\u00f3mo comprar acciones de CRISPR Therapeutics AG (CRSP) - Inversi\u00f3n en acciones de CRISPR Therapeutics AG (CRSP)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/"},"th_TH":{"locale":"th_TH","id":338042,"slug":"how-to-buy-crispr-therapeutics-ag","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 CRISPR Therapeutics AG (CRSP) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 CRISPR Therapeutics AG (CRSP)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/"},"tr_TR":{"locale":"tr_TR","id":338044,"slug":"how-to-buy-crispr-therapeutics-ag","post_title":"CRISPR Therapeutics AG (CRSP) Hisseleri Nas\u0131l Al\u0131n\u0131r - CRISPR Therapeutics AG (CRSP) Hisse Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/"},"vt_VT":{"locale":"vt_VT","id":338040,"slug":"how-to-buy-crispr-therapeutics-ag","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu CRISPR Therapeutics AG (CRSP)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/"},"pt_AA":{"locale":"pt_AA","id":338046,"slug":"how-to-buy-crispr-therapeutics-ag","post_title":"Como comprar a\u00e7\u00f5es da CRISPR Therapeutics AG (CRSP) - Investimento em a\u00e7\u00f5es da CRISPR Therapeutics AG (CRSP)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-crispr-therapeutics-ag\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/337957","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=337957"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/337957\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334126"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=337957"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=337957"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=337957"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}